Department of Pediatrics, Monroe Carrell Jr. Children's Hospital at Vanderbilt, Vanderbilt University School of Medicine, Nashville, TN, USA.
Semin Perinatol. 2010 Jun;34(3):222-30. doi: 10.1053/j.semperi.2010.02.007.
Premature birth and disruption of the normal maturation process leave the immature ductus arteriosus unable to respond to postnatal cues for closure. Strategies that advocate conservative management of the patent ductus arteriosus (PDA) in premature infants are dependent on identification of the symptomatic PDA and understanding the risk factors that predispose to PDA. Exposure of premature infants to unintended vasodilatory stimuli may be one of the risk factors for PDA that is under recognized. In this article, we summarize the clinical factors that are associated with PDA and review commonly used neonatal drugs for their vasodilatory properties. Data demonstrating relaxation of the ductus arteriosus by gentamicin and other aminoglycoside antibiotics, by cimetidine and other H2 receptor antagonists, and by heparin are provided as examples of neonatal therapies that have unanticipated effects that may promote PDA.
早产和正常成熟过程的中断会使未成熟的动脉导管无法对出生后的闭合信号做出反应。提倡对早产儿的动脉导管未闭(PDA)进行保守治疗的策略取决于识别有症状的 PDA 和了解易导致 PDA 的危险因素。早产儿暴露于意外的血管扩张刺激可能是未被充分认识的 PDA 危险因素之一。在本文中,我们总结了与 PDA 相关的临床因素,并回顾了常用的新生儿药物的血管扩张特性。提供了庆大霉素和其他氨基糖苷类抗生素、西咪替丁和其他 H2 受体拮抗剂以及肝素使动脉导管松弛的相关数据,这些数据表明新生儿治疗可能具有意想不到的促进 PDA 的作用。